Literature DB >> 25691774

pVHL/HIF-regulated CD70 expression is associated with infiltration of CD27+ lymphocytes and increased serum levels of soluble CD27 in clear cell renal cell carcinoma.

Melanie Ruf1, Christiane Mittmann2, Anna M Nowicka2, Arndt Hartmann3, Thomas Hermanns4, Cédric Poyet4, Maries van den Broek5, Tullio Sulser4, Holger Moch2, Peter Schraml1.   

Abstract

PURPOSE: CD70, a member of the TNF ligand superfamily, has been shown frequently overexpressed in clear cell renal cell carcinoma (ccRCC). The mechanisms of CD70's upregulation and its role in ccRCC are unknown. EXPERIMENTAL
DESIGN: CD70 expression was immunohistochemically analyzed in 667 RCCs and RCC metastases. Von Hippel-Lindau gene (VHL) mutations, expression patterns of VHL protein (pVHL), hypoxia-inducible factor (HIF) α, and several HIF targets were studied in tissues and cell lines and correlated with CD70 overexpression. Gene promoter analysis was performed to confirm CD70 as HIF target gene. Consecutive tissue sections were immunostained to reveal the relation between CD70-expressing RCCs and tumor-infiltrating lymphocytes positive for the CD70 receptor (CD27). CD70-mediated release of soluble CD27 in RCC was assessed by coculture experiments and sera analysis of patients with RCC.
RESULTS: Elevated CD70 expression was seen in 80% of primary tumors and metastases of ccRCC and correlated with dysregulation of the pVHL/HIF pathway. In vitro analyses demonstrated that CD70 upregulation is driven by HIF. Furthermore, CD27(+) lymphocytes preferentially infiltrate CD70-expressing ccRCCs. CD70-dependent release of soluble CD27 in cocultures may explain the high CD27 levels observed in sera of patients with CD70-expressing ccRCC. The combination of lymphocyte infiltration and CD70 expression in RCC was associated with worse patient outcome.
CONCLUSION: Our findings demonstrate that in ccRCC, CD70 expression is regulated by HIF as a consequence of pVHL inactivation. Increased serum levels of CD27 suggest the existence of CD70-expressing ccRCC, thus representing a potential serum marker for patients suffering from this disease. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25691774     DOI: 10.1158/1078-0432.CCR-14-1425

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  23 in total

1.  Clear cell papillary renal cell carcinoma and renal angiomyoadenomatous tumor: two variants of a morphologic, immunohistochemical, and genetic distinct entity of renal cell carcinoma.

Authors:  Karl-Friedrich Deml; Hans-Ulrich Schildhaus; Eva Compérat; Adriana von Teichman; Martina Storz; Peter Schraml; Joseph V Bonventre; Falko Fend; Barbara Fleige; Andreas Nerlich; Helmut E Gabbert; Nikolaus GaBler; Rainer Grobholz; Seife Hailemariam; Raoul Hinze; Ruth Knüchel; Benoit Lhermitte; Gabriella Nesi; Thomas Rüdiger; Guido Sauter; Holger Moch
Journal:  Am J Surg Pathol       Date:  2015-07       Impact factor: 6.394

2.  Expression of CD70 (CD27L) Is Associated With Epithelioid and Sarcomatous Features in IDH-Wild-Type Glioblastoma.

Authors:  Drew Pratt; Stefania Pittaluga; Maryknoll Palisoc; Patricia Fetsch; Liqiang Xi; Mark Raffeld; Mark R Gilbert; Martha Quezado
Journal:  J Neuropathol Exp Neurol       Date:  2017-08-01       Impact factor: 3.685

3.  CD70, a novel target of CAR T-cell therapy for gliomas.

Authors:  Linchun Jin; Haitao Ge; Yu Long; Changlin Yang; Yifan Emily Chang; Luyan Mu; Elias J Sayour; Gabriel De Leon; Qiong J Wang; James C Yang; Paul S Kubilis; Hongbo Bao; Songsong Xia; Dunyue Lu; Yingjun Kong; Li Hu; Yujiao Shang; Chencheng Jiang; Jing Nie; Shimin Li; Yunhe Gu; Jiahang Sun; Duane A Mitchell; Zhiguo Lin; Jianping Huang
Journal:  Neuro Oncol       Date:  2018-01-10       Impact factor: 12.300

4.  Preclinical Evaluation of Chimeric Antigen Receptors Targeting CD70-Expressing Cancers.

Authors:  Qiong J Wang; Zhiya Yu; Ken-Ichi Hanada; Krishna Patel; David Kleiner; Nicholas P Restifo; James C Yang
Journal:  Clin Cancer Res       Date:  2016-11-01       Impact factor: 12.531

Review 5.  Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts.

Authors:  Yuchen Wang; Hao Zhang; Chao Liu; Zeyu Wang; Wantao Wu; Nan Zhang; Longbo Zhang; Jason Hu; Peng Luo; Jian Zhang; Zaoqu Liu; Yun Peng; Zhixiong Liu; Lanhua Tang; Quan Cheng
Journal:  J Hematol Oncol       Date:  2022-08-17       Impact factor: 23.168

6.  Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia.

Authors:  Mark B Leick; Harrison Silva; Irene Scarfò; Rebecca Larson; Bryan D Choi; Amanda A Bouffard; Kathleen Gallagher; Andrea Schmidts; Stefanie R Bailey; Michael C Kann; Max Jan; Marc Wehrli; Korneel Grauwet; Nora Horick; Matthew J Frigault; Marcela V Maus
Journal:  Cancer Cell       Date:  2022-04-21       Impact factor: 38.585

7.  Molecular Characterization of the Tumor Microenvironment in Renal Medullary Carcinoma.

Authors:  David S Tourigny; Mark Zucker; Minsoo Kim; Paul Russo; Jonathan Coleman; Chung-Han Lee; Maria I Carlo; Ying-Bei Chen; A Ari Hakimi; Ritesh R Kotecha; Ed Reznik
Journal:  Front Oncol       Date:  2022-06-28       Impact factor: 5.738

8.  Interaction of tumor cells with infiltrating lymphocytes via CD70 and CD27 in clear cell renal cell carcinoma.

Authors:  Melanie Ruf; Holger Moch; Peter Schraml
Journal:  Oncoimmunology       Date:  2015-05-29       Impact factor: 8.110

9.  Preclinical data on the combination of cisplatin and anti-CD70 therapy in non-small cell lung cancer as an excellent match in the era of combination therapy.

Authors:  Julie Jacobs; Vanessa Deschoolmeester; Christian Rolfo; Karen Zwaenepoel; Jolien Van den Bossche; Christophe Deben; Karen Silence; Hans de Haard; Christophe Hermans; Sylvie Rottey; Christel Vangestel; Filip Lardon; Evelien Smits; Patrick Pauwels
Journal:  Oncotarget       Date:  2017-05-23

10.  Hypoxia-inducible factor-2 alpha up-regulates CD70 under hypoxia and enhances anchorage-independent growth and aggressiveness in cancer cells.

Authors:  Shojiro Kitajima; Kian Leong Lee; Masaki Fujioka; Wendi Sun; Jia You; Grace Sushin Chia; Hideki Wanibuchi; Shuhei Tomita; Marito Araki; Hiroyuki Kato; Lorenz Poellinger
Journal:  Oncotarget       Date:  2018-04-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.